Taiho Pharmaceutical And Sanofi-Aventis (France) Conclude Licensing Agreement For Oral Pyrimidine Fluoride-Derived Anticancer Agent TS-1
Published: Jul 10, 2006
Tokyo, July 10, 2006 (JCN) - Taiho Pharmaceutical and sanofi-aventis have entered into a licensing agreement for TS-1, an anticancer agent developed by Taiho Pharmaceutical. Under the agreement terms announced on June 4, sanofi-aventis will receive the rights to develop and commercialize the agent worldwide except in Japan and some Asian countries. Sanofi-aventis will make an upfront payment, milestone payments for development and royalties on futures sales to Taiho Pharmaceutical.